Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Receivables: 2013-2020

Historic Change in Receivables for Viridian Therapeutics, Inc.\DE (VRDN) over the last 8 years, with Dec 2020 value amounting to -$99,000.

  • Viridian Therapeutics, Inc.\DE's Change in Receivables rose 94.49% to -$48,000 in Q4 2020 from the same period last year, while for Dec 2020 it was -$99,000, marking a year-over-year decrease of 217.86%. This contributed to the annual value of -$99,000 for FY2020, which is 217.86% down from last year.
  • According to the latest figures from FY2020, Viridian Therapeutics, Inc.\DE's Change in Receivables is -$99,000, which was down 217.86% from $84,000 recorded in FY2019.
  • Viridian Therapeutics, Inc.\DE's 5-year Change in Receivables high stood at $1.4 million for FY2017, and its period low was -$1.4 million during FY2018.
  • Over the past 3 years, Viridian Therapeutics, Inc.\DE's median Change in Receivables value was -$99,000 (recorded in 2020), while the average stood at -$482,333.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 7,080.00% in 2017, then tumbled by 217.86% in 2020.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Change in Receivables stood at $20,000 in 2016, then surged by 7,080.00% to $1.4 million in 2017, then tumbled by 199.72% to -$1.4 million in 2018, then surged by 105.87% to $84,000 in 2019, then slumped by 217.86% to -$99,000 in 2020.